Diagnosis and Natural History Study of Patients With Neurological Conditions
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00001549
Recruitment Status :
First Posted : November 4, 1999
Last Update Posted : March 4, 2008
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by:
National Institutes of Health Clinical Center (CC)
The purpose of this study is to improve understanding of neurological conditions. Patients participating in this study will continue receiving medical care, routine laboratory tests, and diagnostics tests (X-rays, CT-scans, and nuclear imaging), from their primary care physician. Doctors at the NIH plan to follow these patients and offer advice and assistance to their primary care physicians.
Condition or disease
Alzheimer's DiseaseDementiaMovement DisorderMultiple System AtrophyParkinson's Disease
The objective of this protocol is to provide diagnosis and follow Experimental Therapeutics Branch (ETB) patients not currently entered on another research protocol. No investigational treatments will be administered on this protocol, and the NIH physicians will be playing largely a consultative role to the patient's primary physician.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients may be included on this protocol if they have an identifiable neurological disorder or represent a diagnostic puzzle. These disorders would include patients with Parkinson's disease, Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, restless legs syndrome, other cognitive and movement disorders, and diagnostic puzzles.
Patients 18-90 years of age, inclusive, are eligible.